Accelerating Your COVID-19 Vaccine Development

Developing safe and effective SARS-CoV-2 vaccines requires a cohesive approach spanning every stage of your development. Learn how you can apply solutions from Labcorp to accelerate your vaccine studies and reach patients, faster.

Connect with our COVID-19 response team

Accelerate patient recruitment in a competitive landscape

Increase your chances to connect with patients and expedite your recruitment.

  • Labcorp Patient Direct enables access to direct-to-patient recruitment with U.S.-based patients who have expressed interest in participating in clinical trials* and meet initial pre-screen criteria
  • COVID-19 Clinical Trial Connect is designed to accelerate patient recruitment for COVID-19 trials by collecting interested U.S.-based patients to participate in COVID-related clinical trials in their area

Incorporate integral testing into your studies 

Reliably detect an immune response to the SARS-CoV-2 virus in your vaccine studies. 

  • Leverage decades of experience to provide functional, cell-based infectivity assays that assess neutralizing antibody activity, along with state-of-the-art serological assays for the detection and quantitation of SARS-CoV-2 antibody isotype responses (IgG, IgA, IgM)
  • Characterize your vaccine candidates and determine if they elicit a neutralizing antibody response 

You can access a breadth of testing capabilities to screen candidates as part of your vaccine clinical trials or evaluate endpoints of your vaccine trial.

Leverage the unique biobank of recovered patients’ biospecimens 

Access a rich collection of longitudinal data that will be critical for advancing vaccines. 

The COVID-19 RECOVER Biobank aims to build a repository of participants’ biospecimens from three different time points over a year after a patient’s positive COVID-19 test. 

With plans to collect samples from more than 2,000 Labcorp Patient Service Centers across the U.S., these specimens are expected to allow for a variety of testing and analyses – and also provide access to key information regarding patients’ demographics, duration and severity of COVID-19 symptoms, medical history and concomitant medications – to better understand your target population.

A novel biobank to expand your vaccine solutions:

  • Immunogenicity testing
  • DNA analysis
  • Biomarker research
  • Population-based analyses

Apply a holistic approach to advance your COVID-19 vaccine

Our in-depth experience across every stage of drug development allows us to offer you connected insights through the tight partnership of our COVID-19 Response Team with your team to:

  • Accelerate study startup by leveraging our 90 worldwide facilities and our experience collaborating with over 175,000 unique clinical investigators  
  • Conduct nonclinical studies (i.e., immunogenicity, safety) to make rapid go/no-go decisions
  • Leverage Early Phase Development Solutions to assess nonclinical data packages and speed toward clinical trials
  • Strategically incorporate virtual tools and technologies into a decentralized clinical trial
  • Navigate global regulations to meet your next milestone 

Set your study up for success with a partner that can efficiently combine diagnostic and drug development solutions and help your vaccine candidate progress in a competitive landscape.

 Patients can’t wait. Neither can we.™ Together, let’s increase your speed to market and accelerate much needed vaccines.

Related Services

*This service is available for clients working with our clinical solutions team. 

Connect with our COVID-19 Response Team

Contact Us